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Introduction: Mesenchymal stem cells (MSCs) are an attractive cell source for cartilage and bone tissue
engineering given their ability to differentiate into chondrocytes and osteoblasts. However, the common origin of
these two specialized cell types raised the question about the identification of regulatory pathways determining the
differentiation fate of MSCs into chondrocyte or osteoblast.
Methods: Chondrogenesis, osteoblastogenesis, and adipogenesis of human and mouse MSC were induced
by using specific inductive culture conditions. Expression of promyelocytic leukemia zinc-finger (PLZF) or
differentiation markers in MSCs was determined by RT-qPCR. PLZF-expressing MSC were implanted in
a mouse osteochondral defect model and the neotissue was analyzed by routine histology and
microcomputed tomography.
Results: We found out that PLZF is not expressed in MSCs and its expression at early stages of MSC
differentiation is the mark of their commitment toward the three main lineages. PLZF acts as an upstream
regulator of both Sox9 and Runx2, and its overexpression in MSC enhances chondrogenesis and
osteogenesis while it inhibits adipogenesis. In vivo, implantation of PLZF-expressing MSC in mice with
full-thickness osteochondral defects resulted in the formation of a reparative tissue resembling cartilage
and bone.
Conclusions: Our findings demonstrate that absence of PLZF is required for stemness maintenance and its
expression is an early event at the onset of MSC commitment during the differentiation processes of the
three main lineages.Introduction
Bone marrow stromal cells, commonly referred to as
mesenchymal stem cells (MSCs), are nonhematopoietic
cells that display differentiation capacity toward adipo-
cytes, osteoblasts, chondrocytes. MSCs exist in almost
all tissues and are a key cell source for tissue repair and
regeneration [1]. Stem-cell maintenance in the adult
organism is essential for tissue homeostasis initiation of* Correspondence: farida.djouad@inserm.fr
1Inserm, U844, Hôpital Saint Eloi, Montpellier F-34091, France
2Université MONTPELLIER1, UFR de Médecine, Montpellier F-34000, France
Full list of author information is available at the end of the article
© 2014 Djouad et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the ornative tissue regeneration and the response to injury. To
maintain the stem cell pool in the niche, some stem cells
must remain undifferentiated and quiescent. Under spe-
cific circumstances, they can proliferate through cyclic
mitotic divisions. Cells committed to differentiate enter
the meiotic pathway, which comprises a unique program
of gene expression and chromatin remodeling. How does
each MSC decide whether to proliferate or differentiate?
Although the molecular mechanisms controlling this deli-
cate balance are largely unknown, critical transcription
factors involved in the commitment of different MSC-
derived lineages have been identified [2,3]. For example, itLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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lates chondrogenesis, whereas osteoblastic differentiation
is controlled by Runx2, and PPAR-γ is involved in adipo-
cyte commitment [4]. The possibility that an intrinsic
molecule acting upstream these latter transcription factors
can subsequently control MSC “stemness” properties or
lineage-specific commitment has not been described. If
such a factor does exist, it would help to understand the
biology of MSC and the mechanisms regulating their
differentiation.
PLZF (promyelocytic leukemia zinc-finger) also known
as, ZBTB16, ZNF145 or Kruppel-like zinc-finger protein,
belongs to the family of the transcriptional repressors
POK (POZ and Krüppel). In addition to nine Krüppel-
type sequence-specific zinc fingers, PLZF contains a con-
served POZ (poxvirus and zinc finger) domain in its N
terminus [5]. This domain mediates protein-protein in-
teractions and allows POZ domain-containing proteins
to be involved in several differentiation pathways, in-
cluding osteoclastogenesis, hematopoiesis, adipogene-
sis, and muscle differentiation [6]. PLZF expression
profile in early, but not in differentiated hematopoietic
cells, suggests its involvement in stem cell maintenance
and self-renewal [7]. Moreover, PLZF-knockout mice
exhibit defects in patterning of the limb and axial skel-
eton [8]. Together with Gli3 (GLI-Kruppel family mem-
ber 3), PLZF has been described to be specifically
required for stylopod and zeugopod element formation
at very early stages of limb development, before the ini-
tiation of cartilage condensations [9]. In line with these
in vivo studies, it has been shown that PLZF overex-
pression in human MSCs enhances chondrogenesis
[10]. In addition, PLZF was described to play an im-
portant role in early osteoblastic differentiation [11,12].
Regarding adipogenesis, its overexpression was re-
ported to be repressive, and conversely, RNAi-mediated
knockdown of PLZF enhances adipogenesis [13]. This
is in contrast with results described by Liu and co-
workers [10], showing that PLZF knockdown in MSC
decreases adipogenic genes as well as lipid deposit dur-
ing adipogenesis. All together, these studies suggest that
PLZF acts as a key factor in MSC differentiation pro-
cesses. However, because it is well established that a
competition or mutual suppression exists between the
genetic pathways that lead to either chondrocyte or
osteoblast differentiation in mesenchymal progenitors
[14], it is still not clear whether PLZF acts as an in-
ducer of chondrogenesis or osteogenesis.
In early mesenchymal condensations, MSC possess
multidifferentiation potential as they coexpress Sox9,
Runx2, and PPAR-γ [15]. This suggests that these tran-
scription factors are regulated by other factors to initiate
MSC differentiation toward chondrogenic or osteogenic
programs. In the present study, we investigated whetherPLZF may act in concert with these transcription factors
and play a role in the commitment and differentiation of
MSC toward multiple mesodermal lineages.
Materials and methods
Isolation of MSC
The mesenchymal progenitor cell line C3H10T1/2 (there-
after called C3) [16] was grown in complete Dulbecco
modified Eagle medium (DMEM; Sigma, l’Isle d’Abeau,
France) supplemented with 10% fetal calf serum (FCS)
(Hyclone, Perbio, Bezons, France), 2 mM glutamine, 100
U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen,
Cergy, France). Primary MSC were isolated from C57BL/6
(mMSC). Bone marrow was flushed out of long bones,
and the cell suspension (0.5 × 106cells/cm2) was plated in
minimum essential medium (MEM)-α supplemented with
10% fetal bovine serum (FBS) (Hyclone, Thermo Fisher
Scientific, Brebières, France), 2 mM glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin (Lonza, Levallois-
Perret, France), and 2 ng/ml human basic fibroblast
growth factor (bFGF) (R&D Systems, Lille, France). At
subconfluence, cells were replated at the density of 5,000
cells/cm2 and used before passage 10. Human MSC
(hMSC) were isolated from patients after written informed
consent and approval by the General Direction for Re-
search and Innovation, the Ethics Committee from the
French Ministry of Higher Education and Research (regis-
tration number: DC-2009-1052). Bone marrow from tra-
beculae of bone specimens was flushed and expanded in
minimum essential medium α (MEMα; Invitrogen) sup-
plemented with 10% FCS, 2 mM glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin, and 1 ng/mlL basic
fibroblast growth factor (bFGF; R&D Systems, Lille,
France). Confluent hMSCs were used between passage 2
and 4 to ensure homogeneous cell populations. Before
use, hMSC populations were phenotyped by flow cytome-
try (cells were negative for CD34 and CD45 and positive
for CD90, CD105, and CD73).
Plasmid and transfections
pSG5 Expression vector (Stratagene, La Jolla, CA, USA)
containing PLZF (pSG5-PLZF) was a gift from J.D. Licht
and P.J. Martin [17]. C3 cells were stably transfected
by using the calcium-phosphate precipitation technique
with the pSG5-PLZF and pX343 plasmid carrying
the hygromycin B resistance gene as a selectable marker.
Clones were isolated from individual colonies and amp-
lified before analysis with RT-qPCR and immunoflu-
orescence by using anti-PLZF antibody (Santa Cruz
Biotechnology, Le Perray en Yveline, France).
Cell differentiation
Differentiation of MSC was induced by culture in spe-
cific conditions for 21 days. For adipogenesis, murine
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modified Eagle medium (DMEM)-F12 (Invitrogen)
with 16 μM biotin, 18 μM panthotenic acid, 100 μM
ascorbic acid, 5 μg/ml insulin, 0.03 μM dexametha-
sone, 1 μg/ml transferrin and 2 ng/ml triiodothyronine
(T3) (Sigma-Aldrich). Human MSCs were plated at the
density of 8 × 103 cells/cm2 in DMEM-F12 containing
5% newborn calf serum, 1 μM dexamethasone, 50 μM
isobutyl-methylxanthine, and 60 μM indomethacin.
The formation of lipid droplets was visualized with
Oil Red O staining. For osteogenesis and chondro-
genesis, inductive conditions specific for murine or
human MSCs were as already reported [18,19]. After
osteogenic differentiation, mineralized extracellular
matrices were visualized after fixation in 95% ethanol
for 30 minutes and staining with a 2% Alizarin Red
S solution, pH 4.2 (Sigma) [20]. Chondrogenesis was
assessed by immunohistochemistry on paraffin sections
of pellets by using an anti-collagen II antibody (Inter-
chim, Montluçon, France) and the Ultravision Detec-
tion System Anti-polyvalent HRP/DAB kit (Lab Vision,
Francheville, France).
Microarray analysis
Hybridization of Affymetrix HG-U133 plus 2.0 arrays
was described in a previous study [19]. Data can be
found under the GEO accession number GSE10315
[21]. Raw gene-expression data were processed for
normalization and signal calculation with the Expression
Variation software previously described [22]. To deter-
mine differentially expressed genes, comparative occur-
rence analysis was performed by using a recently
described approach [23].
RNA extraction and quantitative PCR
Total RNA was isolated by using RNeasy mini kit (Qiagen
S.A., Courtaboeuf, France) and reverse-transcribed by
using GeneAmp Gold RNA PCR Core kit (Applied Biosys-
tems). Reverse transcriptase quantitative PCR (RT-qPCR)
was performed by using LightCycler 480 SYBR Green I
Master mix and real-time PCR instrument (Roche Applied
Science, Meylan, France). Primers were designed by using
the web-based applications, Primer3 and BLAST at the
National Center for Biotechnology Information. Expres-
sion of the housekeeping gene encoding ribosomal protein
S9 (RPS9) was measured for normalization. The relative
amount of a given mRNA was calculated by using the for-
mulae 2-ΔCt or 2-ΔCCt.
Coloration CM-DiI
Stock solution of the fluorescent cell-tracer CM-DiI
(Molecular Probes, Interchim, Montluçon, France)
was reconstituted at a concentration of 1 μg/μl in di-
methyl sulfoxide (DMSO) and used to label C3 andPLZF-expressing C3 cells (C3-PLZF), as described
previously [24].
Tibial implantation of C3 and C3-PLZF MSCs
The 21- to 23-week-old female severe combined immu-
nodeficient (SCID/Beige) or DBA/1 mice (five per
group) were grown in our animal facilities. The protocol
was approved by the Committee on the Ethics of Animal
Experiments in Languedoc-Roussillon (CEEA-LR 36)
(Permit Number: CEEA-LR-1043). Intratibial injection
model was used to create cartilage and bone lesions and
to inject either C3 or C3-PLZF cells (2.5 × 105 cells) sus-
pended in 10 μl of PBS in the right tibia, as previously
described [25]. In brief, the mice were anesthetized by
using 1.5% to 2% isoflurane and oxygen in induction
chamber. A 3-mm longitudinal incision was made over
the patellar ligament with a scissor. A 25-gauge needle
was introduced in the intraarticular space and inserted
through the proximal tibial plateau to inject the C3 or
C3-PLZF cells into the medullary cavity. The overlying
skin incision was sutured, and animals were allowed im-
mediate postoperative weight-bearing. On day 28 after
cell injection, mice were killed, and the injected tibiae
were submitted to micro-computed tomography (μCt)
and histologic analysis.
Micro-computed tomography
After fixation in 4% formaldehyde for 1 week, entire tib-
iae were scanned with a micro-computed tomograph
(SkyScan 1076; Kontich, Belgium). Each scan was per-
formed by using a 0.025-mm titanium filter and a pixel
size of 9 μm. This provides image data of the mineral-
ized, subchondral bone in both tibia and femur. Then a
3D image was reconstructed by using NRecon software
(SkyScan NRecon version 1.6.6). Misalignment compen-
sation, ring artifacts, and beam-hardening were adjusted
to obtain a correct reconstruction of the joint and long
bones. Bone mineral density (BMD) was evaluated with
CT Analyser software (SkyScan CT Analyser version
1.8.1.4). Calibration was made on μCT images per-
formed on a tube of water and two BMD rods with
BMD values of 0.25 and 0.75 g/cc, respectively. These
three scans were achieved at the same time and by using
the same parameters as for the tibias. After calibration,
BMD was calculated for each knee joint in a well-
defined region of interest corresponding to the area
where PBS or cells were injected (from the beginning of
the tibiae to 2.321 mm of depth).
Histology and immunohistochemistry
Tibias were fixed in 4% paraformaldehyde during
1 week, decalcified in 5% formic acid for 3 days, and
processed for routine histology. Paraffin-embedded tis-
sue sections (5 μm) were rehydrated through a gradient
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O and fast green before examination by light microscopy
or mounted in fluorescent mounting medium (Dako,
Trappes, France) for red fluorescence visualization.
Paraffin sections were also stained with Goldner trichrome,
as described previously [26] to visualize bone in green and
bone marrow in dark purple.
For immunohistochemistry, we used the Ultravision
detection system anti-polyvalent HRP/DAB kit (Lab
Vision; Microm, Francheville, France), according to the
manufacturer’s instructions. For type II collagen immu-
nostaining, samples were first incubated with pepsin
(Sigma) for epitope retrieval. Primary antibody anti-type
II collagen monoclonal mouse antibody (1:50; Interchim)
was incubated for 2 hours at RT. Samples were finally
counterstained with Mayer hematoxylin (Lab Vision) for
3 minutes and mounted with Eukitt (Sigma). Immuno-
staining was imaged with the Digital slide scanner Nano-
Zoomer 2.0-HT (Hamamatsu Ltd, Japan). Immunopositive
extracellular matrix showed a brown staining.
Statistical analysis
Data are expressed as the mean ± SEM of at least three in-
dependent experiments. Student t test was used to com-
pare two treatment groups, and multiple comparisons
were performed by ANOVA corrected by Bonferroni post-
test (***P < 0.001; **P < 0.01; and *P < 0.05).
Results
Induction of PLZF expression during chondrogenesis
In a previous study, we performed a transcriptomic ana-
lysis of MSCs isolated from three different donors and
differentiated into chondrocytes by using the micropellet
culture conditions and either TGF-β3 or BMP-2 as
inducers, or osteoblasts or adipocytes. Their mRNA pro-
files were analyzed at different time points by using
Affymetrix gene chips [19]. In silico analysis was per-
formed by varying the stringency for selection of
regulated genes. Parameters including normalized fold
change (FC) over control value at day 0 (D0), occurrence
in the samples depending on the culture conditions, the
donor, or the time point, were adjusted. We found that
PLZF ranked first of 1,248 transcription factors (TFs) at
7 and 21 days of chondrogenesis, whatever the chondro-
genic inducer (data not shown). At earlier time points,
PLZF expression was greatly induced by TGF-β3, rank-
ing third and fifth of the TF at days 1 and 3, respectively.
An early induced PLZF expression was also observed
from day 3 to day 21 of osteogenesis and at days 1 and 3
of adipogenesis with an FC >2.5 in both cases remaining
stable at all indicated time points (data not shown).
Interestingly, PLZF was not expressed in any of the three
MSC samples (at day 0). By RT-qPCR, we confirmed
that its relative expression during either TGF-β3 orBMP-2-dependent in vitro chondrogenesis was substan-
tially induced (by a 15-fold or 5-fold factor, respectively)
as soon as day 1 of the differentiation process (Figure 1A).
To address whether the absence of PLZF expression was
observed in other MSC samples or stem cells from differ-
ent origins, we assessed PLZF expression in pluripotent
cells including human embryonic stem cells (hESC) and
induced pluripotent stem cells (hiPS). We also analyzed
different mesenchymal tissues such as adipose tissue,
skeletal muscle, and trachea, by using the Amazonia
website [27], which is dedicated to relative comparison
of data collected from analysis of Affymetrix U133 Plus
2.0 microarrays. In line with our results, the absence of
PLZF expression was confirmed in undifferentiated
MSCs (4 more samples), and also in hESC (25 samples)
and hiPS (34 samples). Moreover, we observed a sub-
stantial expression of PLZF in adipose tissue, skeletal
muscle and trachea compared with the stem cells
(Figure 1B). We then constructed a regulatory module
to infer the underlying relations between PLZF and
genes involved in the sequence of events of chondro-
genesis [28], genes related to adipogenesis or osteogen-
esis. A relation between PLZF and predicted target-gene
groups was observed. Indeed, by using the Ingenuity
software to analyze the PLZF-related predicted network,
we found that PLZF might act upstream of the master
regulator of osteogenesis Runx2 and also regulate at
least 19 genes related to the chondrogenesis process and
PPARγ, the key regulator of adipogenesis (Figure 1C).
These results suggest that absence of PLZF expression
might be a signature of the undifferentiated state of multi-
potent stem cells, whereas its expression appears in com-
mitted cells.
PLZF expression signs the commitment of MSCs
To define whether the induction of PLZF expression in
MSCs is restricted to the chondrogenic program, we in-
vestigated its expression profile in MSCs undergoing
osteogenic or adipogenic differentiation. We therefore
assessed the expression profile of PLZF during the differ-
entiation process of bone marrow-derived MSCs (BM-
MSCs) toward the chondroblastic, osteoblastic and
adipocytic lineages by using real-time RT-PCR. We ob-
served an upregulation of PLZF expression level as soon
as day 1 of MSC differentiation toward the three line-
ages. The increased expression level of PLZF was notice-
able until the end of the differentiation processes,
compared with undifferentiated MSCs (Figure 2A). How-
ever, PLZF expression was stable from day 1 to day 21
during adipogenesis and osteogenesis, whereas it peaked
at day 3 and decreased thereafter during chondrogenesis.
We next investigated the expression profile of PLZF dur-
ing the differentiation of synovium- (hSYNO) and adipose
tissue-derived MSC (hASC) that we previously described
Figure 1 Absence of PLZF expression in cells signs their stemness state. (A) Expression profile of PLZF during the chondrogenic
differentiation of MSCs as assessed by microarray analysis. At day 0, absence of PLZF expression was defined as 1, and this was used to calculate
the relative expression at the remaining time points. (B) PLZF expression profile in human MSCs, ESCs, iPSs, adipose tissue, skeletal muscle, and
trachea as reported in the Amazonia website. The signal intensity is shown on the y axis as arbitrary units determined by the GCOS 1.2 software
(Affymetrix). When indicated, the mean expression is significantly different from that in MSCs, hESCs, and hiPS. (C) PLZF-related network was
reconstructed by using the Ingenuity Pathways Analysis Software (IPA) software where PLZF acts upstream of Runx2 and regulates downstream
genes. Blue-shaded genes are genes identified to be involved in chondrogenesis, grey-shaded genes either involved in osteogenesis or
adipogenesis, and unshaded genes are those associated with the identified genes based on pathway analysis.
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MSC [29,30]. We showed that, whatever was the MSC
tested, PLZF was induced as early as day 1 of chondro-
genesis, adipogenesis, and osteogenesis and maintained
during the differentiation (Figure 2B, C). With theexception of hASC, the expression of PLZF remained
stable or slightly increased during adipogenesis or
osteogenesis of both MSC sources. Similar behavior
was observed for chondrogenesis of hSYNO and hASC.
Although some variations of PLZF expression was
Figure 2 PLZF expression profile in the course of MSC differentiation into the three main lineages. Expression profile of PLZF during the
differentiation of human (A) bone marrow- (hBM-MSC), (B) synovium- (hSYNO), and (C) adipose-derived (hASC) MSCs toward the chondroblastic,
osteoblastic, and adipocytic lineages by using RT-qPCR. RT-qPCR data represent the mean ± SEM of three independent experiments.
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origin of MSC, its high expression at day 1 of MSC dif-
ferentiation was indicative of commitment of MSCs to-
ward the three main lineages.
PLZF regulates the osteogenic and chondrogenic master
regulators
The increased expression of PLZF during MSC commit-
ment suggested that it might play a major role in the dif-
ferentiation processes. To address this issue, we tested
whether PLZF overexpression may enhance the differen-
tiation of MSCs toward chondrocytes, osteoblasts, or ad-
ipocytes. For that purpose, we used murine BM-derived
MSCs (mMSCs) and investigated the expression profile
of PLZF during their differentiation process toward the
three lineages. We showed that PLZF expression reached
its maximum at day 7 of osteogenesis and chondrogene-
sis to slightly decrease at day 21 (Figure 3A). During
adipogenesis, PLZF expression was induced at day 7 to
increase further until the end of the differentiation
(Figure 3A).
In parallel, by using the well-characterized mouse MSC
line, C3H10T1/2 (here called C3 cell), we also demon-
strated that PLZF was not expressed in the undifferentiatedcells but was significantly upregulated in the cells induced
to differentiate into the three lineages (Figure 3B). We
therefore decided to use C3 cells to study the role of PLZF
in MSC differentiation. First, we transfected C3 cells to ob-
tain MSC that stably overexpress PLZF. We selected several
clones that were resistant to hygromycin B and expressed
high levels of PLZF. We identified a high-expressing clone,
called C3-PLZF, that was thereafter used in the study
(Figure 3C, D). We then investigated whether PLZF overex-
pression could influence the expression level of the master
regulators of the adipogenic, osteogenic, or chondrogenic
programs. We showed that Sox9 and Runx2, key transcrip-
tion factors of chondrogenesis and osteogenesis, respect-
ively, were significantly increased in C3-PLZF compared
with C3 cells, whereas the master regulator of adipogenesis,
PPAR-γ, was unchanged (Figure 3E). Altogether, these data
suggest that PLZF acts as a transcription factor regulating
both Sox9 and Runx2 TF, suggesting that it might be a
marker of chondro-osteoprogenitor cells.
PLZF regulates the differentiation potential of MSCs
We then determined whether PLZF overexpression
could modulate MSC differentiation potential. We thus
compared the capacities of C3 and C3-PLZF to
Figure 3 Expression level of PLZF in primary mMSC, C3, and C3-PLZF cells. (A) PLZF expression in mMSCs during chondrogenic,
adipogenic, and osteogenic differentiation as assessed by RT-qPCR. (B) Expression profile of PLZF in undifferentiated (D0) and differentiated C3
cells into three lineages; adipogenic (Adipo), osteogenic (Osteo), and chondrogenic cells (Chondro). (C) Expression level of PLZF in undifferentiated
C3 cells and in a clone of C3 cells with high PLZF expression (C3-PLZF), as quantified by using RT-qPCR. (D) Immunofluorescence analysis of C3 and
C3-PLZF by using an anti-PLZF antibody. (E) Expression profile of the master regulators of the chondrogenic, adipogenic, or osteogenic programs,
Sox9, PPARγ, or Runx2, respectively, in the C3 or C3-PLZF cells.
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adipogenic lineages. C3 and C3-PLZF cells induced to
differentiate into chondrocytes, formed a similar pellet,
with an increased production of type II collagen (Col2)
(Figure 4A). Staining in C3-PLZF-derived pellets was
uniform throughout the pellet, whereas it was localized
in the center of the pellets obtained with C3 cells, sug-
gesting a more homogeneous differentiation of C3-PLZF
cells. This observation was supported by the significant
increase in Col2A1 mRNA expression in pellets formed
with C3-PLZF cells, as compared with C3 (Figure 4A).
MSCs cultured in adipogenic medium formed character-
istic intracellular lipid-rich vacuoles that stained positive
with oil red O. Compared with C3, C3-PLZF displayed
a substantially lower ability to form lipid vacuoles
suggesting a reduced degree of adipocytic maturation
(Figure 4B). However, we showed that C3-PLZF differen-
tiated into adipocytes expressed a similar expression
level of fatty-acid-binding protein (FABP)-4 and PPAR-γ
(Figure 4B). Finally, C3-PLZF induced to undergo osteo-
genesis expressed a higher mRNA expression level of
osteocalcin (OC) at day 21 than did C3 cells (Figure 4C).Moreover, under osteogenic conditions, cells cultured
for 21 days produced a mineralized matrix that stained
positive with alizarin red, with the highest level of
mineralization seen in C3-PLZF cultures (Figure 4C). In
summary, PLZF overexpression in C3 resulted in en-
hanced chondrogenesis and osteogenesis, whereas it
inhibited adipocyte maturation.
PLZF-overexpressing MSCs formed cartilage and bone
in vivo
Finally, we determined whether PLZF-overexpressing C3
cells could promote the repair of osteochondral defects
in vivo. We compared the effect of C3 and C3-PLZF in-
jection in lesions that penetrated both the cartilage and
bone through the epiphyseal and growth plates. At
28 days after cell implantation, hindlimbs of DBA/1 mice
were scanned with a micro-computed tomograph to
evaluate bone mineral density (BMD) before histologic
evaluation. A significant increase of the BMD was ob-
served in mice receiving C3-PLZF compared with the
group of mice injected with PBS (Figure 5A). Safranin O
(Saf O) staining of sections revealed a substantial
Figure 4 Role of PLZF on MSC differentiation. (A) Effect of PLZF overexpression on MSC chondrogenic differentiation after 21 days in
micropellet culture. Expression of Sox9 and the cartilage marker Col2A1 in C3 and C3-PLZF, cells assessed by RT-qPCR and immunohistochemical
analysis for collagen II expression in pellets. (B) Effect of PLZF overexpression on MSC adipogenic potential. Expression level of PPAR-γ and
the adipocyte marker (FABP4) determined by RT-qPCR and staining of lipid droplets with oil red O. (C) Effect of PLZF overexpression on MSC
osteogenic potential. Expression level of Runx2 and the osteoblast marker osteocalcin (OC), determined by RT-qPCR, and alizarin red S staining
for mineralization. RT-qPCR data represent the mean ± SEM of three independent experiments.
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lar bone and bone marrow in the group receiving PBS
(Figure 5B3 and B4). After C3 cell injection, a mix of
fibrous tissue and bone filled with bone marrow was
seen by using Saf O staining (Figure 5B5 and B6)
and Goldner trichrome staining for bone identification
(Figure 5C1 and C2). In contrast, in the group of mice
treated with C3-PLZF cells, the defect was filled mostly
by bone tissue with a few cavities of bone marrow as
seen by Saf O (Figure 5B7 and B8) and Goldner tri-
chrome staining (Figure 5C3 and C4).
A similar experiment was also conducted in SCID/Bg
mice. To determine the origin of the neotissue, we stained
the cells with the fluorescent marker CM-DiI before injec-
tion. We showed in this model that C3 injection led to the
formation of fibrous tissue with some fluorescent C3 cells
in the neotissue. No formation of cartilage extracellular
matrix was observed, as revealed by the absence of proteo-
glycans after Saf O or Col2 staining (Figure 6a and c).When C3-PLZF cells were injected, the defects were filled
with cartilage-like tissue that stained positive for Saf O on
the superficial layer (Figure 6d). At higher magnification,
we observed the presence of newly differentiated chondro-
cytes producing Col2-positive matrix and some fibrous
tissue (Figure 6f). Moreover, presence of CM-DiI-positive
injected cells was observed in the neoformed tissue
(Figure 6b and e). Indeed, we showed that a number of
the cells that differentiated into chondrocytes were the
injected C3 or C3-PLZF, as observed by the red fluores-
cence. However, the fluorescent staining of cells did not
cover all the surface of the newly formed tissue. Therefore,
whereas C3-PLZF injection resulted in the formation of
bone in immunocompetent mice, it gave rise to cartilage-
like tissue in SCID mice.
Discussion
We demonstrated the link between PLZF expression
and MSC commitment during their differentiation
Figure 5 C3-PLZF cell injection leads to bone formation in an
osteoarticular defect model in immunocompetent mice. (A)
Quantification of the bone density (g/cm3). (B) Histologic analysis of
tibial sections stained with Safranin O and Fast green. On the top, a
representative control tibia. (C) Goldner trichrome histologic
staining. Tibias were recovered 28 days later.
Figure 6 C3-PLZF cell injection leads to cartilage and bone
formation in an osteoarticular defect model in SCID mice. (a) A
representative histologic section of the tibia of a SCID mouse that
has received naïve C3 cells stained with Safranin O and Fast green.
(b) Distribution of CM-DiI-labeled C3 shown by fluorescence microscopy
as red fluorescent cells. (c) Collagen II-positive staining on tibia sections.
(d) Histologic sections of tibias stained with Safranin O and Fast green.
C3-PLZF cell injection leads to cartilage formation in an osteoarticular
defect model in SCID mouse. (e) Distribution of CM-DiI-labeled C3-PLZF
shown by fluorescence microscopy as red fluorescent cells. (f) Collagen
II-positive staining on tibia sections.
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that although the absence of expression of PLZF in
MSCs signed their undifferentiated state, its early in-
duction predicted their commitment toward adipogene-
sis, chondrogenesis, and osteogenesis. Moreover, this
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underlying MSC fate determination. We showed that
PLZF acted upstream of Sox9 and Runx2, and in vitro, its
overexpression in MSCs increased both their chondro-
genic and osteogenic potential while inhibiting adipogene-
sis. In vivo, implantation of PLZF-overexpressing MSCs
into an intratibial osteochondral defect formed bone
and cartilage. Our findings have therefore important
implications for the role of PLZF in MSC biology and
in particular in their chondrogenic and osteogenic dif-
ferentiation potential.
MSCs are an attractive source for cell therapy and tis-
sue engineering. However, currently, no marker specific
for MSCs has been identified. Herein, we demonstrated
that MSCs as well as, hESCs and iPSs, share in common
the absence of PLZF expression. We further showed a
strong relation between PLZF expression and lineage
commitment. Early upregulation of PLZF after induction
of differentiation of MSC toward the three lineages was
observed independently of the cell source, except during
osteogenic differentiation of ASC.
Another difference between cell sources was noticed for
the expression profile of PLZF during chondrogenesis of
BM-MSC. The reason for these disparities is not known,
but we hypothesized that PLZF may exert different roles,
depending on the source of cells. Indeed, in vitro, by using
both human and mouse MSCs we showed an induction of
PLZF as early as day 1 of the chondrogenic, osteogenic,
and adipogenic differentiation processes. This result sug-
gests that PLZF might be used to interrogate molecularly
the early stages of MSC commitment. Moreover, we
showed that PLZF overexpression affected MSC differen-
tiation potential because it significantly increased chon-
drogenesis and osteogenesis, whereas it inhibited the
maturation of adipocytes. These results are in line with
the fact that PLZF overexpression in C3 cells is associated
with a significant increase in the level of Sox9 and Runx2,
but it did not change the PPAR-γ expression profile, as
well as previous studies highlighting the role of PLZF in
cartilage [10] or bone formation [12]. MSC differentiation
is controlled by the regulated activity of transcription
factor networks, among which, Sox9 and Runx2 co-
operate in a tightly and temporally regulated manner.
The interesting finding of the present study is the pos-
sibility that PLZF may act upstream of these specific
transcription factors. It is likely that such a role is not
through direct binding of PLZF to regulatory sequences
in the promoter region of Sox9 or Runx2 but via inter-
actions with other factors. We therefore propose that
PLZF is an early marker of MSC commitment, which
acts as an upstream regulator of Sox9 and Runx2, pro-
moting chondrogenesis and osteogenesis, respectively.
Interestingly in vivo, we showed that the intratibial im-
plantation of C3-PLZF cells was accompanied byexcessive bone formation in immunocompetent mice,
whereas it filled the defects with a reparative cartilage-
like tissue in the superficial layer in immunodeficient
mice. The newly formed tissue was partly associated
with the presence of the injected cells that were most
numerous after injection in immunodeficient mice. We
cannot determine whether the injected MSCs stimulated
the recruitment and differentiation of endogenous cells
to promote bone or cartilage formation or whether they
proliferated in situ and subsequently lose the fluorescent
staining. Interestingly, the nature of the neotissue
formed after C3-PLZF injection depended on the host
immune status.
In the present study, we used the SCID/bg mouse strain,
which lacks mature T cells, B cells, natural killer cell (NK)
activity, and might harbor macrophage defects [31,32].
Physiologically, mature osteoblasts arising from MSCs
after the activation of different transcription factors,
such as Runx2, can regulate osteoclast activity. Both cell
types are involved in bone remodeling, which is further
regulated by the immune system, and lymphocyte- or
macrophage-derived cytokines are among the most potent
mediators of osteoimmunologic regulation. Indeed, the
bone-protective role of resting T lymphocytes has been
demonstrated in T-cell-deficient mice, which displayed a
significant increase in basal osteoclast number and re-
duced bone density as compared with controls [33]. Fur-
thermore, in vivo depletion of CD4+ and CD8+ T cells
enhances osteoclast formation by a mechanism involving
suppression of osteoprotegerin production by B cells [34].
Among the most prominent cytokines produced by NK
cells are tumor necrosis factor-α (TNF-α) and interferon γ
(IFN-γ), adding to the fact that the SCID/bg mouse envir-
onment is reduced in inflammatory stimuli [35,36]. Cyto-
kines produced by activated monocytes/macrophages have
been described to induce osteoblast differentiation and
matrix mineralization from MSCs [37]. This observation
is in line with studies revealing that osteal macrophages
involved in bone formation or healing are inflammatory
and produce high amounts of TNF-α [38,39]. Irrespec-
tively, the cellular mediators from macrophages were also
shown to act in an autocrine and paracrine fashion to in-
duce imbalance between bone formation and resorption,
either by enhancing the osteoclastic lineage or by acting
on stromal or osteoblastic cells, leading to the loss of bone
stock [40,41]. Moreover, IL-1β and TNF-α display potent
NF-κB–dependent inhibitory effects on cartilage forma-
tion [42]. These different studies highlighted the fact that
immune cells are necessary for bone homeostasis. Similar
findings were observed in the present study, in which
osteoblastogenic differentiation of MSCs took place after
intratibial injection in immunocompetent mice, likely via
the secretion of bone-inducing factors secreted by the sur-
rounding environment. In this model, bone formation was
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planted. On the contrary, in immunodeficient mice, MSC
differentiation was inhibited or greatly reduced, and PLZF
overexpression favored cartilage formation instead of bone
formation. The present results are in agreement with the
findings made by Liu and coworkers on the role of PLZF
as a factor increasing cartilage repair in an osteochondral
defect model [10].
Our study asked furthermore about the contribution
of immune cells to the role of PLZF in MSC differenti-
ation. In addition to the role of immune cells on the bal-
ance between bone formation and bone resorption,
which has been well documented, it may be possible that
absence of T cells may shift the differentiation program
of MSCs toward cartilage instead of bone formation.
This hypothesis, however, needs further investigation.Conclusion
This study demonstrated that PLZF expression is lacking
in undifferentiated stem cells and induced early during
the differentiation of MSCs toward the three main line-
ages. We showed that PLZF induction in MSC acted as
a molecular switch between osteo-chondroprogenitor
and adipogenic progenitor cell fates, according to envir-
onmental conditions. Hence, PLZF could be a key regu-
lator for the “stemness” maintenance of stem cells and
act as an inducer of MSC commitment. This finding im-
proves our knowledge on the dual role of PLZF in MSC
differentiation potential and paves the way for develop-
ing specific therapeutic approaches for cartilage and
bone repair.
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